Pharmaceutical - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 432 results

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

Cardiovascular disease has already cost six EU countries over $100 billion in 2014 alone

28-08-2014

Research by Anglo-Swedish drug major AstraZeneca into the cost burden of cardiovascular disease has shown…

AstraZenecaCardio-vascularEconomy of the European UnionEuropePharmaceuticalResearch

Aspirin may reduce the risks of reoccurring blood clots

Aspirin may reduce the risks of reoccurring blood clots

26-08-2014

Aspirin may be a promising alternative for those who can’t take long-term anticoagulant drugs that…

AspirinCardio-vascularPharmaceuticalResearch

Call for Indian govt to bring more essential drugs under price control from NGOs

Call for Indian govt to bring more essential drugs under price control from NGOs

22-08-2014

Non-governmental organizations in India have jointly issued a letter calling on the country’s government…

Cardio-vascularDiabetesIndiaNational Pharmaceuticals Pricing AuthorityPharmaceuticalPoliticsPricing

FDA expands indication for Eliquis to treatment of DVT and PE

FDA expands indication for Eliquis to treatment of DVT and PE

22-08-2014

US pharma majors Bristol-Myers Squibb and Pfizer late yesterday said that the US Food and Drug Administration…

Boehringer IngelheimCardio-vascularEliquisPfizerPharmaceuticalPulmonary embolismRegulationUSA

Russia’s Peptogen launches production of innovative CV drugs

Russia’s Peptogen launches production of innovative CV drugs

20-08-2014

Sergei Sobyanin, Mayor of Moscow, has officially launched a new Russian plant for the production of innovative…

Cardio-vascularHeart attacksMoscowPeptogenPharmaceuticalProductionRussiaSergey SobyaninStrogino

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

Shares in Cytori fall as it announces suspension of heart disease trial

Shares in Cytori fall as it announces suspension of heart disease trial

07-08-2014

Shares in Cytori Therapeutics declined as much as 29% as it announced it was suspending enrollment in…

Cardio-vascularCytori TherapeuticsIschemic heart diseasePharmaceuticalResearchUSA

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

30-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals have announced that nine…

alirocumabCardio-vascularGeorge YancopoulosPharmaceuticalResearchSanofiUSA

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23-07-2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Milestone appoints Francis Plat as chief medical officer

Milestone appoints Francis Plat as chief medical officer

21-07-2014

Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment…

BoardroomCanadaCardio-vascularFrancis PlatMilestone PharmaceuticalsPharmaceutical

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Proveca reaches agreement with EMA over heart failure drug for children

Proveca reaches agreement with EMA over heart failure drug for children

10-07-2014

UK pharmaceutical company Proveca has reached its fourth key agreement with the European Medicines Agency…

CaptoprilCardio-vascularPharmaceuticalRegulationUK

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Pozen re-files for US approval of PA8140/PA32540

Pozen re-files for US approval of PA8140/PA32540

02-07-2014

US drug firm Pozen has resubmitted the New Drug Application for PA8140/PA32540 (aspirin and omeprazole)…

AspirinCardio-vascularOmeprazolePA8140/PA32540PharmaceuticalPozenRegulationUSA

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

1 to 25 of 432 results

Back to top